ADAGENE INC. SP.ADR Market Cap ($237.92 Million)
Market Cap & Net Worth: ADAGENE INC. SP.ADR (978)
ADAGENE INC. SP.ADR market cap. ADAGENE INC. SP.ADR (F:978) has a market capitalization of $237.92 Million (€203.50 Million) as of November 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #15688 globally and #1521 in its home market, demonstrating a -2.53% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ADAGENE INC. SP.ADR's stock price €3.08 by its total outstanding shares 66072594 (66.07 Million). Also see cash flow conversion of ADAGENE INC. SP.ADR for how efficiently the company converts equity into cash flow.
ADAGENE INC. SP.ADR Market Cap History (2021–2026)
ADAGENE INC. SP.ADR market cap history from 2021 to 2026. Data shows change from $834.25 Million to $152.17 Million (-30.38% CAGR). Check current stock price of ADAGENE INC. SP.ADR for real-time trading data and today's change.
ADAGENE INC. SP.ADR Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ADAGENE INC. SP.ADR's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 978 shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
14.80x
ADAGENE INC. SP.ADR's market cap is 14.80 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $834.25 Million | $10.18 Million | -$73.18 Million | 81.99x | N/A |
| 2022 | $83.43 Million | $9.29 Million | -$79.97 Million | 8.98x | N/A |
| 2023 | $115.10 Million | $18.11 Million | -$18.95 Million | 6.35x | N/A |
| 2024 | $139.81 Million | $103.20K | -$33.42 Million | 1354.74x | N/A |
| 2025 | $113.55 Million | $7.67 Million | -$17.61 Million | 14.80x | N/A |
Competitor Companies of 978 by Market Capitalization
Companies near ADAGENE INC. SP.ADR in the global market cap rankings as of November 4, 2026. Also see 978 total asset value for a full breakdown of the balance sheet.
Key companies related to ADAGENE INC. SP.ADR by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of ADAGENE INC. SP.ADR (2021–2026)
Market capitalization of ADAGENE INC. SP.ADR from 2021 to today. Between 2021 and today, ADAGENE INC. SP.ADR's market cap moved from $834.25 Million to $ 152.17 Million, with a yearly change of -30.38%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €152.17 Million | +34.01% |
| 2025 | €113.55 Million | -18.78% |
| 2024 | €139.81 Million | +21.48% |
| 2023 | €115.10 Million | +37.96% |
| 2022 | €83.43 Million | -90.00% |
| 2021 | €834.25 Million | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of ADAGENE INC. SP.ADR was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $237.92 Million USD |
| MoneyControl | $237.92 Million USD |
| MarketWatch | $237.92 Million USD |
| marketcap.company | $237.92 Million USD |
| Reuters | $237.92 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ADAGENE INC. SP.ADR
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 anti… Read more